{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:17:35Z","timestamp":1791199055878,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Diabetes mellitus is a global public health concern, with diabetic foot infections (DFIs) being common clinical complications among affected patients. Bacterial isolates resistant to commonly used antimicrobial drugs are becoming more prevalent in DFIs. Some research suggests that platelet-rich plasma (PRP) may inhibit bacterial growth, making it a promising biological therapy. Therefore, an in vitro experimental study was conducted on 53 multidrug-resistant (MDR) bacterial strains isolated from DFIs. The isolates were methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA), MDR <jats:italic>Klebsiella pneumoniae<\/jats:italic>, and MDR <jats:italic>Pseudomonas aeruginosa<\/jats:italic>. The antibacterial activity of PRP was assessed using Kirby-Bauer disk diffusion method, broth microdilution method, checkerboard synergy testing, and time-kill assay. The time-kill assay demonstrated that PRP\u2019s antibacterial efficacy peaked during the second hour of incubation for MRSA and <jats:italic>Pseudomonas aeruginosa<\/jats:italic>, but peaked at the first hour for <jats:italic>Klebsiella pneumoniae<\/jats:italic>. However, the PPR\u2019s efficiency against all isolates decreased after the peak point, with no antibacterial activity observed at the 24th h of incubation. Additionally, biofilm inhibition and eradication assays revealed that PRP has no effect on biofilm formation. As a result, PRP has the ability to inhibit bacterial growth, although this effect is transient and depends on the bacterial strain.<\/jats:p>","DOI":"10.1038\/s41598-025-97418-0","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:16:14Z","timestamp":1745986574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Platelet-rich plasma as a potential antimicrobial agent against multidrug-resistant bacteria in diabetic foot infections"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-5134","authenticated-orcid":false,"given":"Engy","family":"Aboelsaad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Amine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Deghady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"El-Attar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"97418_CR1","doi-asserted-by":"publisher","first-page":"e034058","DOI":"10.1136\/bmjopen-2019-034058","volume":"10","author":"PC Banik","year":"2020","unstructured":"Banik, P. C. et al. Risk of diabetic foot ulcer and its associated factors among Bangladeshi subjects: A multicentric cross-sectional study. BMJ Open. 10, e034058 (2020).","journal-title":"BMJ Open."},{"key":"97418_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/XCE.0000000000000210","volume":"9","author":"AH Heald","year":"2020","unstructured":"Heald, A. H. et al. Estimating life years lost to diabetes: outcomes from analysis of National diabetes audit and office of National statistics data. Cardiovasc. Endocrinol. Metab. 9, 183\u2013185 (2020).","journal-title":"Cardiovasc. Endocrinol. Metab."},{"key":"97418_CR3","doi-asserted-by":"publisher","first-page":"110945","DOI":"10.1016\/j.diabres.2023.110945","volume":"204","author":"H Sun","year":"2023","unstructured":"Sun, H. et al. Erratum to IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 204, 110945 (2023).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"97418_CR4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1086\/511036","volume":"44","author":"LA Lavery","year":"2007","unstructured":"Lavery, L. A., Armstrong, D. G., Murdoch, D. P., Peters, E. J. & Lipsky, B. A. Validation of the infectious diseases society of America\u2019s diabetic foot infection classification system. Clin. Infect. Dis. 44, 562\u2013565 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"97418_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00125-008-0940-0","volume":"51","author":"L Prompers","year":"2008","unstructured":"Prompers, L. et al. Prediction of outcome in individuals with diabetic foot ulcers: Focus on the differences between individuals with and without peripheral arterial disease. Diabetologia 51, 747\u2013755 (2008).","journal-title":"Diabetologia"},{"key":"97418_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/1687-4293.132774","volume":"8","author":"AA Hefni","year":"2013","unstructured":"Hefni, A. A. et al. Bacteriological study of diabetic foot infection in Egypt. J. Arab. Soc. Med. Res. 8, 26\u201332 (2013).","journal-title":"J. Arab. Soc. Med. Res."},{"key":"97418_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4239\/wjd.v2.i2.24","volume":"2","author":"JL Richard","year":"2011","unstructured":"Richard, J. L., Sotto, A. & Lavigne, J. P. New insights in diabetic foot infection. World J. Diabetes. 2, 24\u201332 (2011).","journal-title":"World J. Diabetes"},{"key":"97418_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/DSS.0000000000000665","volume":"42","author":"R Alves","year":"2016","unstructured":"Alves, R., Grimalt, R. & Randomized Placebo-Controlled Double-Blind, Half-Head study to assess the efficacy of Platelet-Rich plasma on the treatment of androgenetic alopecia. Dermatol. Surg. 42, 491\u2013497 (2016).","journal-title":"Dermatol. Surg."},{"key":"97418_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.oto.2009.10.006","volume":"20","author":"AP Wroblewski","year":"2010","unstructured":"Wroblewski, A. P., Mejia, H. A. & Wright, V. J. Application of platelet-rich plasma to enhance tissue repair. Oper. Tech. Orthop. 20, 98\u2013105 (2010).","journal-title":"Oper. Tech. Orthop."},{"key":"97418_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3109\/09546634.2015.1094178","volume":"27","author":"MD Lynch","year":"2016","unstructured":"Lynch, M. D. & Bashir, S. Applications of platelet-rich plasma in dermatology: A critical appraisal of the literature. J. Dermatolog Treat. 27, 285\u2013289 (2016).","journal-title":"J. Dermatolog Treat."},{"key":"97418_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2180-13-47","volume":"13","author":"L Drago","year":"2013","unstructured":"Drago, L., Bortolin, M., Vassena, C., Taschieri, S. & Del Fabbro, M. Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. BMC Microbiol. 13, 47 (2013).","journal-title":"BMC Microbiol."},{"key":"97418_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5604\/17331331.1234992","volume":"66","author":"RL Aggour","year":"2017","unstructured":"Aggour, R. L. & Gamil, L. Antimicrobial effects of platelet-rich plasma against selected oral and periodontal pathogens. Pol. J. Microbiol. 66, 31\u201337 (2017).","journal-title":"Pol. J. Microbiol."},{"key":"97418_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1051\/ject\/200638174","volume":"38","author":"PA Everts","year":"2006","unstructured":"Everts, P. A. et al. Platelet-rich plasma and platelet gel: A review. J. Extra Corpor. Technol. 38, 174\u2013187 (2006).","journal-title":"J. Extra Corpor. Technol."},{"key":"97418_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.orthres.2004.08.015","volume":"23","author":"E Anitua","year":"2005","unstructured":"Anitua, E. et al. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J. Orthop. Res. 23, 281\u2013286 (2005).","journal-title":"J. Orthop. Res."},{"key":"97418_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1089\/ten.teb.2018.0309","volume":"25","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. Platelet-Rich plasma for the treatment of tissue infection: Preparation and clinical evaluation. Tissue Eng. Part. B Rev. 25, 225\u2013236 (2019).","journal-title":"Tissue Eng. Part. B Rev."},{"key":"97418_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12929-017-0324-1","volume":"24","author":"M Suthar","year":"2017","unstructured":"Suthar, M., Gupta, S., Bukhari, S. & Ponemone, V. Treatment of chronic non-healing ulcers using autologous platelet rich plasma: A case series. J. Biomed. Sci. 24, 16 (2017).","journal-title":"J. Biomed. Sci."},{"key":"97418_CR17","first-page":"113","volume":"28","author":"AA Hasan","year":"2019","unstructured":"Hasan, A. A., Heiba, A. A., Metwally, L., Kishk, R. M. & Kamel, N. Antimicrobial effect of platelet rich plasma and platelet gel against Staphylococcus aureus isolated from surgical site infections: An in vitro study. J. Med. Microbiol. 28, 113\u2013120 (2019).","journal-title":"J. Med. Microbiol."},{"key":"97418_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.15373\/2249555X\/MAY2013\/10","volume":"3","author":"J Apurva","year":"2013","unstructured":"Apurva, J., Barate, D. & Musaddiq, M. Biofilm forming abilities and antibiotic susceptibility pattern of clinical isolates of Staphylococcus aureus. Indian J. Appl. Res. 3, 41\u201344 (2013).","journal-title":"Indian J. Appl. Res."},{"key":"97418_CR19","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1177\/0363546509349921","volume":"37","author":"TE Foster","year":"2009","unstructured":"Foster, T. E., Puskas, B. L., Mandelbaum, B. R., Gerhardt, M. B. & Rodeo, S. A. Platelet-rich plasma: From basic science to clinical applications. Am. J. Sports Med. 37, 2259\u20132272 (2009).","journal-title":"Am. J. Sports Med."},{"key":"97418_CR20","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.joca.2013.07.017","volume":"21","author":"Y Zhu","year":"2013","unstructured":"Zhu, Y. et al. Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: A review. Osteoarthr. Cartil. 21, 1627\u20131637 (2013).","journal-title":"Osteoarthr. Cartil."},{"key":"97418_CR21","doi-asserted-by":"crossref","unstructured":"Cavallo, C. et al. Platelet-rich plasma: the choice of activation method affects the release of bioactive molecules. Biomed. Res. Int.. 6591717 (2016). (2016).","DOI":"10.1155\/2016\/6591717"},{"key":"97418_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.avsg.2016.04.023","volume":"38","author":"M Ahmed","year":"2017","unstructured":"Ahmed, M., Reffat, S. A., Hassan, A. & Eskander, F. Platelet-rich plasma for the treatment of clean diabetic foot ulcers. Ann. Vasc. Surg. 38, 206\u2013211 (2017).","journal-title":"Ann. Vasc Surg."},{"key":"97418_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4239\/wjd.v9.i10.172","volume":"9","author":"T Hirase","year":"2018","unstructured":"Hirase, T., Ruff, E., Surani, S. & Ratnani, I. Topical application of platelet-rich plasma for diabetic foot ulcers: A systematic review. World J. Diabetes. 9, 172\u2013179 (2018).","journal-title":"World J. Diabetes"},{"key":"97418_CR24","doi-asserted-by":"publisher","first-page":"e3280","DOI":"10.1002\/dmrr.3280","volume":"36","author":"BA Lipsky","year":"2020","unstructured":"Lipsky, B. A. et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab. Res. Rev. 36, e3280 (2020).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"97418_CR25","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.3390\/jcm10091948","volume":"10","author":"G Matta-Gutierrez","year":"2021","unstructured":"Matta-Gutierrez, G. et al. The influence of multidrug-resistant bacteria on clinical outcomes of diabetic foot ulcers: a systematic review. J. Clin. Med. 10, 1948 (2021).","journal-title":"J. Clin. Med."},{"key":"97418_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1534734614521236","volume":"13","author":"X Ji","year":"2014","unstructured":"Ji, X., Jin, P., Chu, Y., Feng, S. & Wang, P. Clinical characteristics and risk factors of diabetic foot ulcer with multidrug-resistant organism infection. Int. J. Low Extrem Wounds. 13, 64\u201371 (2014).","journal-title":"Int. J. Low Extrem Wounds"},{"key":"97418_CR27","doi-asserted-by":"crossref","unstructured":"Chen, Y., Ding, H., Wu, H. & Chen, H. L. The Relationship between osteomyelitis complication and drug-resistant infection risk in diabetic foot ulcer: A meta-analysis. Int. J. Low Extrem Wounds. 16, 183\u2009\u2013\u200990      (2017).","DOI":"10.1177\/1534734617728642"},{"key":"97418_CR28","first-page":"367","volume":"65","author":"CC Clawson","year":"1971","unstructured":"Clawson, C. C. & White, J. G. Platelet interaction with bacteria: reaction phases and effects of inhibitors. Am. J. Pathol. 65, 367\u2013380 (1971).","journal-title":"Am. J. Pathol."},{"key":"97418_CR29","first-page":"35","volume":"5","author":"MC Robson","year":"2005","unstructured":"Robson, M. C. et al. Integrating the results of phase IV (postmarketing) clinical trial with four previous trials reinforces the position that regranex (Becaplermin) gel 0.01% is an effective adjunct to the treatment of diabetic foot ulcers. J. Appl. Res. 5, 35\u201345 (2005).","journal-title":"J. Appl. Res."},{"key":"97418_CR30","first-page":"50351","volume":"74","author":"H Li","year":"2013","unstructured":"Li, H. & Li, B. PRP as a new approach to prevent infection: Preparation and in vitro antimicrobial properties of PRP. J. Vis. Exp. 74, 50351 (2013).","journal-title":"J. Vis. Exp."},{"key":"97418_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/IDR.S186651","volume":"12","author":"T Li","year":"2019","unstructured":"Li, T. et al. Platelet-rich plasma plays an antibacterial, anti-inflammatory and cell proliferation-promoting role in an in vitro model for diabetic infected wounds. Infect. Drug Resist. 12, 297\u2013309 (2019).","journal-title":"Infect. Drug Resist."},{"key":"97418_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1537-2995.2012.03668.x","volume":"53","author":"T Burnouf","year":"2013","unstructured":"Burnouf, T., Chou, M. L., Wu, Y. W., Su, C. Y. & Lee, L. W. Antimicrobial activity of platelet (PLT)-poor plasma, PLT-rich plasma, PLT gel, and solvent\/detergent-treated PLT lysate biomaterials against wound bacteria. Transfusion 53, 138\u2013146 (2013).","journal-title":"Transfusion"},{"key":"97418_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/09537104.2013.863859","volume":"26","author":"CM Edelblute","year":"2015","unstructured":"Edelblute, C. M., Donate, A. L., Hargrave, B. Y. & Heller, L. C. Human platelet gel supernatant inactivates opportunistic wound pathogens on skin. Platelets 26, 13\u201316 (2015).","journal-title":"Platelets"},{"key":"97418_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/scrt218","volume":"4","author":"PR Amable","year":"2013","unstructured":"Amable, P. R. et al. Platelet-rich plasma Preparation for regenerative medicine: Optimization and quantification of cytokines and growth factors. Stem Cell. Res. Ther. 4, 67 (2013).","journal-title":"Stem Cell. Res. Ther."},{"key":"97418_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.tibtech.2008.11.009","volume":"27","author":"DM Dohan Ehrenfest","year":"2009","unstructured":"Dohan Ehrenfest, D. M., Rasmusson, L. & Albrektsson, T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 27, 158\u2013167 (2009).","journal-title":"Trends Biotechnol."},{"key":"97418_CR36","first-page":"529","volume":"14","author":"E Anitua","year":"1999","unstructured":"Anitua, E. Plasma rich in growth factors: preliminary results of use in the Preparation of future sites for implants. Int. J. Oral Maxillofac. Implants. 14, 529\u2013535 (1999).","journal-title":"Int. J. Oral Maxillofac. Implants"},{"key":"97418_CR37","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/jor.20278","volume":"25","author":"LV Schnabel","year":"2007","unstructured":"Schnabel, L. V. et al. Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. J. Orthop. Res. 25, 230\u2013240 (2007).","journal-title":"J. Orthop. Res."},{"key":"97418_CR38","first-page":"1369","volume":"49","author":"MA Abd El-Rahman","year":"2020","unstructured":"Abd El-Rahman, M. A., Al-Hayeg, O. M. I., Aboulyazid, A. B. M. & Gaafar, A. M. The role of platelet-rich plasma in the treatment of diabetic foot ulcers. Al-Azhar Sci. Med. Soc. 49, 1369\u20131376 (2020).","journal-title":"Al-Azhar Sci. Med. Soc."},{"key":"97418_CR39","first-page":"68","volume":"52","author":"VR Driver","year":"2006","unstructured":"Driver, V. R., Hanft, J., Fylling, C. P. & Beriou, J. M. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 52, 68\u201370 (2006).","journal-title":"Ostomy Wound Manage."},{"key":"97418_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7603\/s40730-014-0008-3","volume":"1","author":"TDX Tran","year":"2014","unstructured":"Tran, T. D. X., Le, P. T. B. & Van Pham, P. Diabetic foot ulcer treatment by activated platelet rich plasma: a clinical study. Biomed. Res. Ther. 1, 1\u20136 (2014).","journal-title":"Biomed. Res. Ther."},{"key":"97418_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0939-4753(04)80029-2","volume":"14","author":"G Saldalamacchia","year":"2004","unstructured":"Saldalamacchia, G. et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutr. Metab. Cardiovasc. Dis. 14, 395\u2013396 (2004).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"97418_CR42","doi-asserted-by":"crossref","unstructured":"Chen, L., Wang, C., Liu, H., Liu, G. & Ran, X. Antibacterial effect of autologous platelet-rich gel derived from subjects with diabetic dermal ulcers in vitro. J. Diabetes Res.. 269527 (2013). (2013).","DOI":"10.1155\/2013\/269527"},{"key":"97418_CR43","first-page":"468","volume":"22","author":"N Yuan","year":"2008","unstructured":"Yuan, N. et al. Preparation of autologous platelet-rich gel for diabetic refractory dermal ulcer and growth factors analysis from it. Chin. J. Reparative Reconstruct. Surg.. 22, 468\u2013471 (2008).","journal-title":"Chin. J. Reparative Reconstruct. Surg."},{"key":"97418_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jpha.2015.11.005","volume":"6","author":"M Balouiri","year":"2016","unstructured":"Balouiri, M., Sadiki, M. & Ibnsouda, S. K. Methods for in vitro evaluating antimicrobial activity: A review. J. Pharm. Anal. 6, 71\u201379 (2016).","journal-title":"J. Pharm. Anal."},{"key":"97418_CR45","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00068-018-0957-0","volume":"45","author":"RA \u00c7etinkaya","year":"2019","unstructured":"\u00c7etinkaya, R. A. et al. Platelet-rich plasma as an additional therapeutic option for infected wounds with multi-drug resistant bacteria: In vitro antibacterial activity study. Eur. J. Trauma. Emerg. Surg. 45, 555\u2013565 (2019).","journal-title":"Eur. J. Trauma. Emerg. Surg."},{"key":"97418_CR46","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1302\/0301-620X.89B3.18491","volume":"89","author":"TM Bielecki","year":"2007","unstructured":"Bielecki, T. M. et al. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: An in vitro study. J. Bone Joint Surg. Br. 89, 417\u2013420 (2007).","journal-title":"J. Bone Joint Surg. Br."},{"key":"97418_CR47","doi-asserted-by":"publisher","first-page":"746809","DOI":"10.3389\/fvets.2021.746809","volume":"8","author":"AR Attili","year":"2021","unstructured":"Attili, A. R. et al. Antibacterial properties of canine platelet-rich plasma and other non-transfusional hemo-components: An in vitro study. Front. Vet. Sci. 8, 746809 (2021).","journal-title":"Front. Vet. Sci."},{"key":"97418_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12934-023-02122-1","volume":"22","author":"AA Abdelaziz","year":"2023","unstructured":"Abdelaziz, A. A., Kamer, A. M. A., Al-Monofy, K. B. & Al-Madboly, L. A. Pseudomonas aeruginosa\u2019s greenish-blue pigment pyocyanin: Its production and biological activities. Microb. Cell. Fact. 22, 110 (2023).","journal-title":"Microb. Cell. Fact."},{"key":"97418_CR49","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00068-017-0852-0","volume":"44","author":"RA Cetinkaya","year":"2018","unstructured":"Cetinkaya, R. A. et al. The efficacy of platelet-rich plasma gel in MRSA-related surgical wound infection treatment: An experimental study in an animal model. Eur. J. Trauma. Emerg. Surg. 44, 859\u2013867 (2018).","journal-title":"Eur. J. Trauma. Emerg. Surg."},{"key":"97418_CR50","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/jor.20519","volume":"26","author":"DJ Moojen","year":"2008","unstructured":"Moojen, D. J. et al. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J. Orthop. Res. 26, 404\u2013410 (2008).","journal-title":"J. Orthop. Res."},{"key":"97418_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0378-1097(03)00856-5","volume":"230","author":"I Keren","year":"2004","unstructured":"Keren, I., Kaldalu, N., Spoering, A., Wang, Y. & Lewis, K. Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230, 13\u201318 (2004).","journal-title":"FEMS Microbiol. Lett."},{"key":"97418_CR52","first-page":"86","volume":"66","author":"ME Olson","year":"2002","unstructured":"Olson, M. E., Ceri, H., Morck, D. W., Buret, A. G. & Read, R. R. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can. J. Vet. Res. 66, 86\u201392 (2002).","journal-title":"Can. J. Vet. Res."},{"key":"97418_CR53","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/iwj.13545","volume":"18","author":"OJ Smith","year":"2021","unstructured":"Smith, O. J., Wicaksana, A., Davidson, D., Spratt, D. & Mosahebi, A. An evaluation of the bacteriostatic effect of platelet-rich plasma. Int. Wound J. 18, 448\u2013456 (2021).","journal-title":"Int. Wound J."},{"key":"97418_CR54","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/jor.24584","volume":"38","author":"JM Gilbertie","year":"2020","unstructured":"Gilbertie, J. M. et al. Platelet-rich plasma lysate displays antibiofilm properties and restores antimicrobial activity against synovial fluid biofilms in vitro. J. Orthop. Res. 38, 1365\u20131374 (2020).","journal-title":"J. Orthop. Res."},{"key":"97418_CR55","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/wound.2011.0333","volume":"1","author":"C Attinger","year":"2012","unstructured":"Attinger, C. & Wolcott, R. Clinically addressing biofilm in chronic wounds. Adv. Wound Care (New Rochelle. 1, 127\u2013132 (2012).","journal-title":"Adv. Wound Care (New Rochelle"},{"key":"97418_CR56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/1534734615595736","volume":"15","author":"S Sun","year":"2016","unstructured":"Sun, S. et al. Combating Superbug without antibiotic on a postamputation wound in a patient with diabetic foot. Int. J. Low Extrem Wounds. 15, 74\u201377 (2016).","journal-title":"Int. J. Low Extrem Wounds"},{"key":"97418_CR57","doi-asserted-by":"crossref","unstructured":"Li, H. & Li, B. PRP as a new approach to prevent infection: Preparation and in vitro antimicrobial properties of PRP. J. Vis. Exp. 74, (2013).","DOI":"10.3791\/50351-v"},{"key":"97418_CR58","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00005373-197602000-00002","volume":"16","author":"NS Levine","year":"1976","unstructured":"Levine, N. S., Lindberg, R. B., Mason, A. D. & Pruitt, B. A. The quantitative swab culture and smear: A quick, simple method for determining the number of viable aerobic bacteria on open wounds. J. Trauma. 16, 89\u201394 (1976).","journal-title":"J. Trauma."},{"key":"97418_CR59","unstructured":"Tille, P. Bailey & Scott\u2019s diagnostic microbiology-E-Book 14th edn (Mosby, 2015)."},{"key":"97418_CR60","first-page":"49","volume":"36","author":"AW Bauer","year":"1966","unstructured":"Bauer, A. W., Kirby, W. M., Sherris, J. C. & Turck, M. Antibiotic susceptibility testing by a standardized single disk method. Tech. Bull. Regist Med. Technol. 36, 49\u201352 (1966).","journal-title":"Tech. Bull. Regist Med. Technol."},{"key":"97418_CR61","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 31th ed.; Suppl M100 CLSI. (2021)."},{"key":"97418_CR62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijid.2018.02.013","volume":"70","author":"N Saltoglu","year":"2018","unstructured":"Saltoglu, N. et al. Influence of multidrug resistant organisms on the outcome of diabetic foot infection. Int. J. Infect. Dis. 70, 10\u201314 (2018).","journal-title":"Int. J. Infect. Dis."},{"key":"97418_CR63","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41598-018-19419-6","volume":"8","author":"J Etulain","year":"2018","unstructured":"Etulain, J. et al. An optimised protocol for platelet-rich plasma Preparation to improve its angiogenic and regenerative properties. Sci. Rep. 8, 1513 (2018).","journal-title":"Sci. Rep."},{"key":"97418_CR64","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/0974-2077.150734","volume":"7","author":"R Dhurat","year":"2014","unstructured":"Dhurat, R. & Sukesh, M. Principles and methods of preparation of platelet-rich plasma: A review and Author\u2019s perspective. J. Cutan. Aesthet. Surg. 7, 189\u2013197 (2014).","journal-title":"J. Cutan. Aesthet. Surg."},{"key":"97418_CR65","doi-asserted-by":"publisher","first-page":"598816","DOI":"10.3389\/fcell.2020.598816","volume":"8","author":"DV Pachito","year":"2020","unstructured":"Pachito, D. V., Bagattini, \u00c2. M., de Almeida, A. M., Mendrone-J\u00fanior, A. & Riera, R. Technical procedures for Preparation and administration of platelet-rich plasma and related products: A scoping review. Front. Cell. Dev. Biol. 8, 598816 (2020).","journal-title":"Front. Cell. Dev. Biol."},{"key":"97418_CR66","doi-asserted-by":"publisher","first-page":"2","DOI":"10.46582\/jsrm.1201002","volume":"12","author":"SC Huber","year":"2016","unstructured":"Huber, S. C. et al. In vitro study of the role of thrombin in platelet rich plasma (PRP) preparation: Utility for gel formation and impact in growth factors release. J. Stem Cells Regen Med. 12, 2\u20139 (2016).","journal-title":"J. Stem Cells Regen Med."},{"key":"97418_CR67","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nprot.2007.521","volume":"3","author":"I Wiegand","year":"2008","unstructured":"Wiegand, I., Hilpert, K. & Hancock, R. E. Agar and broth Dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3, 163\u2013175 (2008).","journal-title":"Nat. Protoc."},{"key":"97418_CR68","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0006-2952(95)02230-9","volume":"51","author":"JJ Martinez-Irujo","year":"1996","unstructured":"Martinez-Irujo, J. J., Villahermosa, M. L., Alberdi, E. & Santiago, E. A checkerboard method to evaluate interactions between drugs. Biochem. Pharmacol. 51, 635\u2013644 (1996).","journal-title":"Biochem. Pharmacol."},{"key":"97418_CR69","unstructured":"Garcia, L. & Synergism Testing Broth microdilution checkerboard and broth macrodilution methods. In: (ed Garcia, L. S.) Clinical Microbiology Procedures Handbook, 3rd ed.; American Society of Microbiology, 140\u2013162 (2014)."},{"key":"97418_CR70","first-page":"1","volume":"19","author":"AL Barry","year":"1999","unstructured":"Barry, A. L. et al. Methods for determining bactericidal activity of antimicrobial agents. Clin. Lab. Stand. Inst. 19, 1\u201314 (1999).","journal-title":"Clin. Lab. Stand. Inst."},{"key":"97418_CR71","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12866-018-1321-6","volume":"18","author":"CD Cruz","year":"2018","unstructured":"Cruz, C. D., Shah, S. & Tammela, P. Defining conditions for biofilm Inhibition and eradication assays for Gram-positive clinical reference strains. BMC Microbiol. 18, 173 (2018).","journal-title":"BMC Microbiol."},{"key":"97418_CR72","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1038\/s41596-021-00515-3","volume":"16","author":"EF Haney","year":"2021","unstructured":"Haney, E. F., Trimble, M. J. & Hancock, R. E. W. Microtiter plate assays to assess antibiofilm activity against bacteria. Nat. Protoc. 16, 2615\u20132632 (2021).","journal-title":"Nat. Protoc."},{"key":"97418_CR73","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1128\/AAC.00691-08","volume":"53","author":"JJ LiPuma","year":"2009","unstructured":"LiPuma, J. J. et al. In vitro activities of a novel nanoemulsion against burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species. Antimicrob. Agents Chemother. 53, 249\u2013255 (2009).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97418-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97418-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97418-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:04:25Z","timestamp":1745989465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97418-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97418"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97418-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study follows the principles of the Declaration of Helsinki. The study proposal was approved by the Ethics Committee at the High Institute of Public Health, Alexandria University, Egypt (Approval number: 00014691). Informed consent was obrained from each participant in this study. All methods were performed in accordance with the relevant guidelines and regulations for ethics approval and consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15145"}}